Compare
International Stem Cell Corp vs Aclaris Therapeutics, Inc. vs Jaguar Health, Inc. vs Whitehawk Therapeutics, Inc.
| Latest fiscal year | International Stem Cell Corp ISCO | Aclaris Therapeutics, Inc. ACRS | Jaguar Health, Inc. JAGX | Whitehawk Therapeutics, Inc. WHWK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.10M | $7.83M | $11.51M | $7.14M |
| Revenue growth (YoY) | +0.2% | -58.2% | -1.5% | -72.5% |
| Gross margin | 55.7% (computed) | 73.3% (computed) | 67.2% (computed) | 89.4% (computed) |
| Operating margin | -2.9% | -975.9% | -398.8% | n/m |
| Net margin | -4.6% | -829.6% | -465.4% | -288.3% |
| Net income | -$418.0K | -$64.92M | -$53.58M | -$20.60M |
| EPS (Diluted) | -$0.05 | -$0.53 | -$22.97 | -$0.33 |
| Operating cash flow | $8.0K | -$47.11M | -$23.69M | -$97.43M |
| Free cash flow | -$35.0K | -$47.22M | n/a | -$97.98M |
| Cash & equivalents | n/a | $19.96M | $968.0K | $37.57M |
| Total assets | $4.82M | $160.46M | $38.32M | $150.83M |
| Total liabilities | $4.58M | $57.38M | $57.01M | $14.52M |
| Shareholders' equity | -$4.06M | $103.08M | -$18.69M | $136.31M |
| Return on year-end equity | n/a | -63.0% | n/a | -15.1% |
| Shares outstanding | 8.00M | 120.50M | n/a | 47.15M |
Revenue, most recent five fiscal years
| Fiscal year | International Stem Cell Corp | Aclaris Therapeutics, Inc. | Jaguar Health, Inc. | Whitehawk Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $9.10M Ended 2025-12-31 | $7.83M Ended 2025-12-31 | $11.51M Ended 2025-12-31 | $7.14M Ended 2025-12-31 |
| 1 year earlier | $9.09M Ended 2024-12-31 | $18.72M Ended 2024-12-31 | $11.69M Ended 2024-12-31 | $25.98M Ended 2024-12-31 |
| 2 years earlier | $7.79M Ended 2023-12-31 | $31.25M Ended 2023-12-31 | $9.76M Ended 2023-12-31 | $24.35M Ended 2023-12-31 |
| 3 years earlier | $8.18M Ended 2022-12-31 | $29.75M Ended 2022-12-31 | $11.96M Ended 2022-12-31 | $15.22M Ended 2022-12-31 |
| 4 years earlier | $7.18M Ended 2021-12-31 | $6.76M Ended 2021-12-31 | $4.33M Ended 2021-12-31 | $14.00M Ended 2021-12-31 |